HRP20040077A2 - Crystalline forms vi and vii of atorvastatin-calcium - Google Patents

Crystalline forms vi and vii of atorvastatin-calcium

Info

Publication number
HRP20040077A2
HRP20040077A2 HR20040077A HRP20040077A HRP20040077A2 HR P20040077 A2 HRP20040077 A2 HR P20040077A2 HR 20040077 A HR20040077 A HR 20040077A HR P20040077 A HRP20040077 A HR P20040077A HR P20040077 A2 HRP20040077 A2 HR P20040077A2
Authority
HR
Croatia
Prior art keywords
atorvastatin
vii
calcium
crystalline forms
crystalline
Prior art date
Application number
HR20040077A
Other languages
English (en)
Inventor
M Satyanarayana Reddy
Chakilam Nagaraju
Gudipati Srinivasulu
Katakam Sinivas
Sagyam Rajeswar Reddy
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of HRP20040077A2 publication Critical patent/HRP20040077A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20040077A 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin-calcium HRP20040077A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin calcium

Publications (1)

Publication Number Publication Date
HRP20040077A2 true HRP20040077A2 (en) 2004-06-30

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040077A HRP20040077A2 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin-calcium

Country Status (19)

Country Link
EP (2) EP2292600A1 (cs)
JP (1) JP2005500351A (cs)
KR (1) KR20040019043A (cs)
CN (1) CN100471836C (cs)
AU (1) AU2002255479B2 (cs)
BG (1) BG108518A (cs)
BR (1) BR0211488A (cs)
CA (1) CA2454500C (cs)
CZ (1) CZ2004126A3 (cs)
EE (1) EE200400048A (cs)
HR (1) HRP20040077A2 (cs)
IL (2) IL159626A0 (cs)
MX (1) MXPA04000889A (cs)
NO (1) NO20040390L (cs)
NZ (1) NZ530785A (cs)
PL (1) PL368647A1 (cs)
RU (1) RU2304139C2 (cs)
WO (1) WO2003011826A1 (cs)
ZA (1) ZA200400573B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma HEMICALCIC ATORVASTATIN FORM VII
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
NZ527048A (en) * 2000-12-27 2004-12-24 Ciba Sc Holding Ag Crystalline forms of atorvastatin
KR100724515B1 (ko) * 2002-02-15 2007-06-04 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법
US7122681B2 (en) 2002-02-19 2006-10-17 Teva Pharmaceutical Industries, Ltd. Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
FI120344B (fi) 2004-03-17 2009-09-30 Ranbaxy Lab Ltd Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
AU2005223491A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
SI1771455T1 (sl) * 2004-07-16 2016-09-30 Lek Pharmaceuticals D.D. Oksidacijski razgradni produkti atorvastatin kalcija
EP1771412A2 (en) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
JP2007512357A (ja) 2004-09-28 2007-05-17 テバ ファーマシューティカル インダストリーズ リミティド 不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法
BRPI0519996A2 (pt) 2004-10-28 2009-04-07 Warner Lambert Co processo para formar atorvastatina amorfa
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
SI1148049T1 (en) 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
WO2001036384A1 (en) 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma HEMICALCIC ATORVASTATIN FORM VII
HUP0303555A3 (en) * 2000-11-16 2005-08-29 Teva Pharma Hydrolysis of [r(r
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NZ527048A (en) * 2000-12-27 2004-12-24 Ciba Sc Holding Ag Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Also Published As

Publication number Publication date
NO20040390L (no) 2004-01-29
IL159626A0 (en) 2004-06-01
BR0211488A (pt) 2004-08-17
WO2003011826A1 (en) 2003-02-13
EP2292600A1 (en) 2011-03-09
CN100471836C (zh) 2009-03-25
IL159626A (en) 2013-04-30
PL368647A1 (en) 2005-04-04
JP2005500351A (ja) 2005-01-06
EE200400048A (et) 2004-04-15
RU2004103470A (ru) 2005-06-20
RU2304139C2 (ru) 2007-08-10
CA2454500A1 (en) 2003-02-13
BG108518A (en) 2004-08-31
KR20040019043A (ko) 2004-03-04
CA2454500C (en) 2009-11-10
EP1414796A1 (en) 2004-05-06
AU2002255479B2 (en) 2008-09-11
CN1537098A (zh) 2004-10-13
NZ530785A (en) 2005-10-28
ZA200400573B (en) 2005-05-11
CZ2004126A3 (cs) 2004-12-15
MXPA04000889A (es) 2004-06-03

Similar Documents

Publication Publication Date Title
HRP20040077A2 (en) Crystalline forms vi and vii of atorvastatin-calcium
TW479494U (en) Structure of pillow
IL162323A0 (en) Preparation of orlistat and orlistat crystalline forms
HUP0402536A3 (en) Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof
EP1430054A4 (en) PURIFICATION AND CRYSTALLINE FORMS OF ZALEPLON
IL159266A (en) Crystalline forms of fexofenadine and processes for the preparation thereof
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
GB0115581D0 (en) Method of mass spectometry
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
IL161608A0 (en) Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
AU2002322445A1 (en) Crystals and structures of arnb aminotransferases
AU2002357159A8 (en) Manufacture of trialkylaluminum compounds and alpha-alcohols
TW493722U (en) Improved structure of lampwick
EP1414427A4 (en) KAVALACTONE COMPOSITIONS AND METHODS OF USE
IL157243A0 (en) Preparation of n-methylparoxetine and related intermediate compounds
EP1392460A4 (en) AMINOSILANOL HYDROFLUORIDES AND THEIR USE
TW484490U (en) Structural improvement of multiple-functional wrench
HU0104370D0 (en) Honeyed schnaps of oerseg
SI1448564T1 (sl) Substituirane indolizinu podobne spojine in postopki uporabe
GB0127380D0 (en) Formation of small crystals
GB0111083D0 (en) Formation of small crystals
TW484488U (en) Improved structure of quick-withdrawn wrench
TW493490U (en) Improved structure of wrench
AU2002365245A8 (en) Crystal structure of yqej and uses thereof
TW494780U (en) Structure of swimmeret

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn